Intervention not reported
Transjugular intrahepatic portosystemic shunt (7 RCTs; 452 participants) · people with liver cirrhosis and ascites
It is very uncertain whether the intervention changes transjugular intrahepatic portosystemic shunt (7 RCTs; 452… (very low certainty).
1 finding from 1 review
HR 0.84 [0.6, 1.18]
Studies not reported
Very low
Intervention not reported
No active treatment (No direct RCT) · people with liver cirrhosis and ascites
It is very uncertain whether the intervention changes no active treatment (No direct RCT) (very low certainty).
1 finding from 1 review
HR 1.66 [0.46, 6.99]
Studies not reported
Very low
Intervention not reported
Loop diuretics (No direct RCT) · people with liver cirrhosis and ascites
It is very uncertain whether the intervention changes loop diuretics (No direct RCT) (very low certainty).
1 finding from 1 review
HR 0.71 [0.23, 2.16]
Studies not reported
Very low
Intervention not reported
Paracentesis plus reinfusion (1 RCT; 24 participants) · people with liver cirrhosis and ascites
It is very uncertain whether the intervention changes paracentesis plus reinfusion (1 RCT; 24 participants) (very low certainty).
1 finding from 1 review
HR 0.77 [0.23, 2.68]
Studies not reported
Very low
Intervention not reported
Interventions · people with liver cirrhosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Rifaximin (1 RCT, 299 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (1 RCT, 299 participants) (very low certainty).
1 finding from 1 review
OR 1.01 [0, 853.21]
Studies not reported
Very low
Intervention not reported
Norfloxacin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (no direct RCT) (very low certainty).
1 finding from 1 review
OR 11.85
Studies not reported
Very low
Intervention not reported
Rifaximin (3 RCTs, 418 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (3 RCTs, 418 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Ciprofloxacin (3 RCT; 255 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes ciprofloxacin (3 RCT; 255 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Norfloxacin (1 RCT, 68 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (1 RCT, 68 participants) (very low certainty).
1 finding from 1 review
HR 0.93 [0.31, 3.44]
Studies not reported
Very low
Intervention not reported
Ciprofloxacin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes ciprofloxacin (no direct RCT) (very low certainty).
1 finding from 1 review
HR 0.62 [0.12, 3.31]
Studies not reported
Very low
Intervention not reported
Rifaximin (2 RCTs, 106 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (2 RCTs, 106 participants) (very low certainty).
1 finding from 1 review
HR 7.8 [0.13, 4647.11]
Studies not reported
Very low
Intervention not reported
Norfloxacin (3 RCTs, 255 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (3 RCTs, 255 participants) (very low certainty).
1 finding from 1 review
HR 0.16 [0, 1.56]
Studies not reported
Very low
Intervention not reported
No active intervention · people with liver cirrhosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Norfloxacin + neomycin (1 RCT, 22 participants) · people with liver cirrhosis
The intervention may leads to lower norfloxacin + neomycin (1 RCT, 22 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Norfloxacin + rifaximin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin + rifaximin (no direct RCT) (very low certainty).
1 finding from 1 review
Intervention not reported
Rifaximin (3 RCTs, 575 participants) · people with liver cirrhosis
The intervention may leads to lower rifaximin (3 RCTs, 575 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Norfloxacin (3 RCTs, 439 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (3 RCTs, 439 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Rifaximin (3 RCTs, 479 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (3 RCTs, 479 participants) (very low certainty).
1 finding from 1 review
HR 0.57 [0.33, 1]
Studies not reported
Very low
Intervention not reported
Norfloxacin (4 RCTs, 546 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (4 RCTs, 546 participants) (very low certainty).
1 finding from 1 review
HR 0.74 [0.49, 1.09]
Studies not reported
Very low